Status:
TERMINATED
Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation
Lead Sponsor:
Asociación para Evitar la Ceguera en México
Conditions:
Macular Thickening
Macular Edema
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether topical nepafenac (qid) is effective in preventing and treating macular thickening related pan-retinal photocoagulation in patients with diabetic reti...
Detailed Description
Objective: To evaluate the effect of topical nepafenac 0.1 %, in preventing and in treating macular thickening related to pan-retinal photocoagulation in diabetic patients. Material and methods: This ...
Eligibility Criteria
Inclusion
- Patients with Severe and proliferative Diabetic Retinopathy
- Symmetric severity grade on both eyes
- Best corrected visual acuity better than 20/80
Exclusion
- Clinical significant macular edema
- Lens opacity
- Ocular surgery 6 months or less before recruit
- Uveitis history
- Actual use of topical or systemic non-steroidal anti inflammatory agents
- Actual or history of other macular diseases
- Ocular surface diseases
- Vitreomacular traction syndrome
- Other vascular retinal diseases different to diabetic retinopathy
- Actual or history of use of topical prostaglandin analogues
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2009
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00801905
Start Date
August 1 2008
End Date
March 1 2009
Last Update
May 30 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Asociación Para Evitar la Ceguera en México I.A.P.
Mexico City, Mexico, 004030
2
Asociacion para Evitar la Ceguera en Mexico I.A.P.
Mexico City, Mexico, 04030